Original Research ARTICLE
Polydopamine-functionalized CA-(PCL-ran-PLA) nanoparticles for target delivery of docetaxel and chemo-photothermal therapy of breast cancer
- 1Department of Anesthesiology, Harvard Medical School, United States
- 2Department of Surgical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, China
- 3Sir Run Run Shaw Hospital, China
- 4Department of Cancer Pharmacology, Hangzhou Normal University, China
Current limitations of cancer therapy include the lack of effective strategy for target delivery of chemotherapeutic drugs, and the difficulty of achieving significant efficacy by single treatment. Herein, we reported a synergistic chemo-photothermal strategy based on aptamer (Apt)-polydopamine (pD) functionalized CA-(PCL-ran-PLA) nanoparticles (NPs) for effective delivery of docetaxel (DTX) and enhanced therapeutic effect. The developed DTX-loaded Apt-pD-CA-(PCL-ran-PLA) NPs achieved promising advantages, such as i) improved drug loading content (LC) and encapsulation efficiency (EE) initiated by star-shaped copolymer CA-(PCL-ran-PLA); ii) effective target delivery of drugs to tumor sites by incorporating AS1411 aptamers; iii) significant therapeutic efficacy caused by synergistic chemo-photothermal treatment. In addition, the pD coating strategy with simple procedures could address the contradiction between targeting modification and maintaining formerly excellent bio-properties. Therefore, with excellent bio-properties and simple preparation procedures, the DTX-loaded Apt-pD-CA-(PCL-ran-PLA) NPs effectively increased thelocal drug concentration in tumor sites, minimized side effects, and significantly eliminated tumors, indicating the promising application of these NPs for cancer therapy.
Keywords: Polydopamine coating, star-shaped copolymer, aptamer, Target delivery, chemo-photothermal therapy
Received: 19 Jan 2018;
Accepted: 05 Feb 2018.
Edited by:Chao Wang, University of North Carolina at Chapel Hill, United States
Reviewed by:Yingjie Yu, Tufts University, United States
Jun Wu, Sun Yat-sen University, China
Xiaoxue Zhang, Stony Brook University, United States
Copyright: © 2018 Kong, Deng, Sun, Chen and Sui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Prof. Yiding Chen, Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Surgical Oncology, Hangzhou, China, firstname.lastname@example.org
Prof. Xinbing Sui, Hangzhou Normal University, Department of Cancer Pharmacology, Hangzhou, MA, China, email@example.com